Results 211 to 220 of about 41,944 (264)

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cancers (Basel)
Gąsowska-Bodnar A, Gąsowska-Bajger B, Żołnierek A, Żołnierek J, Bodnar L.   +4 more
europepmc   +1 more source

A SERS-based biosensor for optical monitoring of PARP1 trapping dynamics and high-throughput screening of modulators. [PDF]

J Nanobiotechnology
Xu S, Wang Z, Li B, Wang J, Fang S, Huang W, Liu Z, Li H, Xiang J, Xu S, Liang C.   +10 more
europepmc   +1 more source

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer. [PDF]

J Exp Clin Cancer Res
Formenti L, Abramo F, Dellavedova G, Dematteis V, Decio A, Grasselli C, Fabbrizio P, Brunelli L, Giavazzi R, Ghilardi C.   +9 more
europepmc   +1 more source

Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis. [PDF]

J Ovarian Res
Zhu Y, Zhou X, Liu K, Zhu H.
europepmc   +1 more source

APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. [PDF]

Sci Rep
Rivera M, Liu L, Enlund S, Lim CE, Zhang H, Yang K, Sasik R, Crews LA, Fisch KM, Eskander RN, Holm F, Jiang Q.   +11 more
europepmc   +1 more source

Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells. [PDF]

Sci Rep
Roehrle J, Perugachi-Heinsohn A, Gatzemeier F, Christiansen S, Petersen C, Rothkamm K, Betz C, Kriegs M, Zech HB, Rieckmann T.   +9 more
europepmc   +1 more source

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. [PDF]

Rev Cardiovasc Med
Ma J, Li C, Wang W, Fan X, Wei T, Ma X, Wang Y, Feng C, Yu J.   +8 more
europepmc   +1 more source

Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation. [PDF]

Front Oncol
You Q, Gong L, Chen Y, Dinglin X, Cheng Z, Xia Q, Xie J, Zhao J, Su F.   +8 more
europepmc   +1 more source

Case Report: Olaparib combined with temozolomide and atezolizumab in a case of <i>BRCA2</i>-mutated small-cell transformation of lung adenocarcinoma. [PDF]

Front Oncol
Liu M, Gao P, Liu F, Li D, Wang Y, Yu J.
europepmc   +1 more source

Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. [PDF]

Cells
Mortan LF, Isingizwe ZR, Benbrook DM.
europepmc   +1 more source